author-photo

H. Janicot

67

Papers

1028

Citations

Citation Trend

Filter By

Papers (49) Sort By

Journal Conference Others

Maintenance targeted therapy compared to standard of care (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the phase II randomized UNICANCER/IFCT1301- SAFIR02-LUNG intergroup trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacité et tolérance de l’immunothérapie par anti-PD1/PDL1 dans le CBNPC métastatique avec mutation BRAF, HER2 ou MET, amplification MET ou translocation RET. GFPC 01-2018

2020 Revue des Maladies Respiratoires Actualités
Show All
- Source
- Cite
- Save
Citations (0)
First-Line Carboplatin Plus Pemetrexed with Pemetrexed Maintenance in HIV+ Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: The Phase II IFCT-1001 CHIVA Trial.

2020 European Respiratory Journal
Show All
- Source
- Cite
- Save
Citations (5)
Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma

2020 Medicine
Show All
- Source
- Cite
- Save
Citations (10)
Outcomes of advanced Non-Small Cell Lung Cancer patients From the IFCT Biomarkers France study by KRAS Mutation Subtypes

2020
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.

2020 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (68)
Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

2019 Cancer Medicine
Show All
- Source
- Cite
- Save
Citations (2)
Health-related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (6)
Le statut télomérique dans le cancer bronchopulmonaire : un nouveau biomarqueur du pronostic et de la résistance à l’immunothérapie

2019 Morphologie
Show All
- Source
- Cite
- Save
Citations (0)
MA05.05 Post-Discontinuation Treatments in IFCT-GFPC-0701 MAPS Trial: Real-World Effectiveness of 2nd-Line (2L) Treatments for Mesothelioma

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)